Tivozanib (AV-951)

DRUG4 trials

Sponsors

AVEO Pharmaceuticals, Inc.

Conditions

Advanced Renal Cell CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellSolid Tumors

Phase 1

An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00826878

AVEO Pharmaceuticals, Inc.Carcinoma, Non-Small-Cell Lung

Start: 2009-01-31End: 2011-05-31Updated: 2012-06-28

Phase 2

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

CompletedNCT00502307

AVEO Pharmaceuticals, Inc.Carcinoma, Renal Cell

Start: 2007-10-31End: 2010-08-31Updated: 2020-09-01

Phase 3

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

CompletedNCT01030783

AVEO Pharmaceuticals, Inc.Advanced Renal Cell Carcinoma

Start: 2009-12-31End: 2013-06-30Updated: 2019-10-28

Unknown Phase

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

TerminatedNCT01369433

AVEO Pharmaceuticals, Inc.Solid Tumors

Start: 2010-06-30End: 2015-10-31Updated: 2020-09-01

Related Papers

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial

The Oncologist2023-06-143 citations

Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial.

Journal of Clinical Oncology2022-06-01

The effect of geography and the availability of second-line therapy on overall survival in a one-way crossover design study in renal cell carcinoma.

Journal of Clinical Oncology2016-05-202 citations

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).

Journal of Clinical Oncology2015-05-207 citations